{
    "id": 23114,
    "cites": 36,
    "cited_by": 4,
    "reference": [
        "Abud, M.J., Hall, B., Helmers, C., 2015. An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile. PLoS ONE 10, e0124257. doi:10.1371/journal.pone.0124257 Amin, T., Kesselheim, A.S., 2012. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades. Health Aff (Millwood) 31, 2286\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2294. doi:10.1377/hlthaff.2012.0107 Basheer, S., Reddy, P., 2008. The \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Efficacy\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d of Indian Patent Law: Ironing out the Creases in Section 3(d) (SSRN Scholarly Paper No. ID 1086254). Social Science Research Network, Rochester, NY.",
        "Barbosa, D.B. 2013. Patents and the Emerging Markets of Latin America: Brazil. In Emerging Markets and the World Patent Order, edited by Frederick M. Abbott, Carlos M. Correa, and Peter Drahos, 135\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c51. Edward Elgar Publishing.",
        "Basso, M., 2006. Intervention of health authorities in patent examination: the Brazilian practice of the prior consent. International Journal of Intellectual Property Management 1, 54\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c74.",
        "doi:10.1504/IJIPM.2006.011022 Berndt, E.R., Cockburn, I.M., 2014. The Hidden Cost Of Low Prices: Limited Access To New Drugs In India. Health Aff 33, 1567\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1575. doi:10.1377/hlthaff.2013.130 Burdon, M., Sloper, K., 2003. The art of using secondary patents to improve protection. J. Med.",
        "Mark. 3, 226\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c238. doi:10.1057/palgrave.jmm.5040125 Carley, M., Hedge, D., Marco, A., 2015. What Is the Probability of Receiving a U.S. Patent. Yale J.L. & Tech. 17, 203.",
        "Christie, A.F., Dent C., Liddicoat, J. 2016. The Examination Effect: A Comparison of the Outcome of Patent Examination in the US, Europe and Australia. John Marshall Review of Intellectual Property Law 16, 21-43.",
        "Correa, C.M., 2014. Tackling the Proliferation of Patents: How to Avoid Undue Limitations to Competition and the Public Domain (No. Research Paper 52). South Centre.",
        "Correa, C.M., 2007. Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective. ICTSD.",
        "Correa, C.M., Balleri, C., Giulietti, M., Lavopa, F., Musetti, C., Palopoli, G., Pippo, T., De la Puente, C., Lowenstein, V., 2011. Patentes, suministro de medicamentos y protecci\u00c3\u0083\u00c2\u00b3n de la Salud P\u00c3\u0083\u00c2\u00bablica; Patents, supply of medicines and protection of public health. Rev. argent. salud publica 2, 19\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c27.",
        "de Rassenfosse, G., Jaffe, A., Webster, E., 2016. Low-quality Patents in the Eye of the Beholder: Evidence from Multiple Examiners (No. w22244). National Bureau of Economic Research, Cambridge, MA.",
        "Dimitrov, M., 2009. Piracy and the State: The Politics of Intellectual Property Rights in China. Cambridge University Press.",
        "Drahos, P., 2010. The Global Governance of Knowledge: Patent Offices and Their Clients. Cambridge University Press.",
        "Drahos, P., 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Trust Me\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d: Patent Offices in Developing Countries. American Journal of Law & Medicine 34, 151.",
        "Duggan, M., Garthwaite, C., Goyal, A., 2016. The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u00a0. American Economic Review 106, 99\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c135. doi:10.1257/aer.20141301 Dutfield, G., Suthersanen, U., 2005. Harmonisation or differentiation in intellectual property protection? The lessons of history. Prometheus 23, 131\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c147. doi:10.1080/08109020500085528 Eisenberg, R.S., 2008. Pharma\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Nonobvious Problem. Lewis & Clark L. Rev, Articles 12, 375\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c430.",
        "Ellery, T. Hansen, N. 2012. Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand. Wiley.",
        "European Commission, 2009. Pharmaceutical Sector Inquiry Report. Frakes, M., Wasserman, M., forthcoming. Is the Time Allocated to Review Patent Applications Inducing Examiners to Grant Invalid Patents?: Evidence from Micro-Level Application Data. Review of Economics and Statistics.",
        "GAO, 2016. Patent Office Should Define Quality, Reassess Incentives, and Improve Clarity (No.",
        "GAO-16-490). Government Accountability Office, Washington, D.C. Hemphill, C.S., Sampat, B.N., 2011. When Do Generics Challenge Drug Patents? Journal of Empirical Legal Studies 8, 613\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c649. doi:10.1111/j.1740-1461.2011.01235.x Hopkins, M.M., Mahdi, S., Patel, P., Thomas, S.M., 2007. DNA patenting: the end of an era? Nature Biotechnology 25, 185\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c187. doi:10.1038/nbt0207-185 Howard, L., 2007. Use of Patents in Drug Lifecycle Management. Journal of Generic Medicines 4, 230\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c236. doi:10.1057/palgrave.jgm.4950065 Jaffe, A.B., Lerner, J., 2004. Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress, and What to Do About It. Princeton University Press.",
        "Jensen, P.H., Palangkaraya, A., Webster, E., 2006. Disharmony in international patent office decisions. Federal Circuit Bar Journal 15, 679\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c704.",
        "Kapczynski, A., 2013. Engineered in India: Patent Law 2.0. New England Journal of Medicine 369, 2163\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2163. doi:10.1056/NEJMc1311602 Kapczynski, A., 2009. Harmonization and its Discontents: A Case Study of TRIPS Implementation in India\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Pharmaceutical Sector. California Law Review 97, 1571\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1649.",
        "Kapczynski, A., Park, C., Sampat, B., 2012. Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Secondary\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Pharmaceutical Patents. PLoS ONE 7, e49470. doi:10.1371/journal.pone.0049470 Kesselheim, A.S., 2007. Intellectual property policy in the pharmaceutical sciences: The effect of inappropriate patents and market exclusivity extensions on the health care system. The AAPS Journal 9, E306\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cE311. doi:10.1208/aapsj0903033 Kunisawa, V.Y.M., 2009. Patenting Pharmaceutical Inventions on Second Medical Uses in Brazil.",
        "The Journal of World Intellectual Property 12, 297\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c316. doi:10.1111/j.1747-1796.2009.00362.x Lanjouw, J.O., Pakes, A., Putnam, J., 1998. How to Count Patents and Value Intellectual Property: The Uses of Patent Renewal and Application Data. The Journal of Industrial Economics 46, 405\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c432. doi:10.1111/1467-6451.00081 Lemley, M.A., Moore, K.A., 2004. Ending Abuse of Patent Continuations. Boston University Law Review 84, 63\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c118. doi:10.2139/ssrn.462404 Lemley, M.A., Sampat, B., 2012. Examiner Characteristics and Patent Office Outcomes. Review of Economics and Statistics 94, 817\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c827. doi:10.1162/REST_a_00194 Lemley, M., Sampat, B.N., 2008. Is the Patent Office a Rubber Stamp? Emory Law Journal 58, 181-.",
        "Lerner, J., 2000. 150 Years of Patent Protection (Working Paper No. 7478). National Bureau of Economic Research.",
        "Levitsky, S., Murillo, M.V., 2009. Variation in Institutional Strength. Annual Review of Political Science 12, 115\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c133. doi:10.1146/annurev.polisci.11.091106.121756 L\u00c3\u0083\u00c2\u00b6fgren, H., Williams, O.D., 2013. The New Political Economy of Pharmaceuticals: Production, Innnovation and TRIPS in the Global South. Palgrave Macmillan.",
        "Maskus, K.E., 2000. Intellectual Property Rights in the Global Economy. Institute for International Economics, Washington, DC.",
        "Moir, H.V.J., 2013. Empirical Evidence on the Inventive Step. European Intellectual Property Review 35, 246\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c252.",
        "PhRMA. 2016. Special 301 Submission 2016. http://phrma-docs.phrma.org/files/dmfile/special-301-review.pdf Rathod, S.K. 2010. Ever-Greening: A Status Check in Selected Countries. Journal of Generic Medicines 7, 227-242.",
        "Reichman, J.H., 2009. Intellectual Property in the Twenty-First Century: Will the Developing Countries Lead or Follow? Houston Law Review 46, 1115\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1185.",
        "Sampat, B.N., Amin, T., 2013. How Do Public Health Safeguards in Indian Patent Law Affect Pharmaceutical Patenting in Practice? Journal of Health Politics, Policy, and Law 38, 735\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c55.",
        "Sampat, B.N., Shadlen, K.C., 2015a. Drug patenting in India: looking back and looking forward. Nature Reviews Drug Discovery 14, 519\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c520.",
        "Sampat, B.N., Shadlen, K.C., 2015b. TRIPS Implementation and Secondary Pharmaceutical Patenting in Brazil and India. St Comp Int Dev 50, 228\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c257. doi:10.1007/s12116-015-9181-7 Shadlen, K.C., 2011. The Political Contradictions of Incremental Innovation: Lessons from Pharmaceutical Patent Examination in Brazil. Politics & Society 39, 143\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c174. doi:10.1177/0032329211402601 Schultz, M. and Madigan, K. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Long Wait for Innovation: The Global Patent Pendency Problem.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Center for the Protection of Intellectual Property.",
        "http://cpip.gmu.edu/wp-content/uploads/2016/10/Schultz-Madigan-The-Long-Wait-for-Innovatio n-The-Global-Patent-Pendency-Problem.pdf Silva, H.M., 2008. Avalia\u00c3\u0083\u00c2\u00a7\u00c3\u0083\u00c2\u00a3o da an\u00c3\u0083\u00c2\u00a1lise dos pedidos de patentes farmac\u00c3\u0083\u00c2\u00aauticas feita pela Anvisa no cumprimento do mandato legal da anu\u00c3\u0083\u00c2\u00aancia pr\u00c3\u0083\u00c2\u00a9via. ENSP, Rio de Janeiro.",
        "South Centre, 2011. The Doha Declaration on TRIPS and Public Health Ten Years Later: The State of ImplementationPolicy Brief 7, November 2011.",
        "Sternitzke, C., 2010. Knowledge sources, patent protection, and commercialization of pharmaceutical innovations. Research Policy 39, 810\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c821. doi:10.1016/j.respol.2010.03.001 UNAIDS, 2011. Doha+10 TRIPS flexibilities and access to antiretroviral therapy: Lessons from the past, opportunities for the future.",
        "USPTO, 2015. Maintenance Fee Register. https://www.google.com/googlebooks/uspto-patents-maintenance-fees.html#1981-present USTR, n.d. Special 301 [WWW Document]. URL https://ustr.gov/issue-areas/intellectual-property/Special-301 (accessed 7.28.16).",
        "Webster, E., Jensen, P.H., Palangkaraya, A., 2014. Patent examination outcomes and the national treatment principle. The RAND Journal of Economics 45, 449\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c469. doi:10.1111/1756-2171.12053 Yamauchi, I. and Nagaoka, S. 2015. An Economic Analysis of Deferred Examination System: Evidence from a Policy Reform in Japan. International Journal of Industrial Organization 39: 19\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c28. doi:10.1016/j.ijindorg.2015.01.003."
    ]
}